Human cytomegalovirus neutralizing antibodies and use thereof
AssigneeInstitute for Research in Biomedicine
InventorsAntonio LANZAVECCHIA, Annalisa MACAGNO
Life of this patent
Estimating the term…
Abstract
The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
Claims19
1-53. (canceled)
An isolated antibody, or an antigen binding fragment thereof, comprising the CDR1, CDR2, and CDR3 sequences of the heavy and light chain variable region sequences set forth in SEQ ID NOs:
- 348 and 349, respectively.
An isolated antibody, or an antigen binding fragment thereof, comprising heavy and light chain variable region CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 336, 337, and 338, respectively, and SEQ ID NOs:
- 339, 340, and 341, respectively.
(canceled)
An isolated antibody, or antigen binding fragment thereof, comprising heavy and light chain variable region sequences having at least 90% identity to the sequences set forth in SEQ ID NOs:
- 348 and 349, respectively.
(canceled)
(canceled)
Dependencies are inferred from the claim text.